XML 110 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Principal Group subsidiaries and associated companies
 12 Months Ended
Dec. 31, 2022
Disclosure of subsidiaries [abstract]  
Principal Group subsidiaries and associated companies
31. Principal Group subsidiaries and associated companies
The following table lists the principal subsidiaries controlled by Novartis, associated companies in which ­Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD 25 million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.

As at December 31, 2022
Share
capital1
Equity
interest
Algeria
Société par actions SANDOZ
Algiers
DZD
650.0
m
100%
Argentina
Novartis Argentina S.A.
Buenos Aires
ARS
906.1
m
100%
Australia
Novartis Australia Pty Ltd
Macquarie Park, NSW
AUD
2
100%
Novartis Pharmaceuticals Australia Pty Ltd
Macquarie Park, NSW
AUD
3.8
m
100%
Sandoz Pty Ltd
Macquarie Park, NSW
AUD
11.6
m
100%
Austria
Novartis Austria GmbH
Vienna
EUR
1.0
m
100%
Novartis Pharma GmbH
Vienna
EUR
1.1
m
100%
Sandoz GmbH
Kundl
EUR
32.7
m
100%
EBEWE Pharma Ges.m.b.H Nfg. KG
Unterach am Attersee
EUR
1.0
m
100%
Bangladesh
Novartis (Bangladesh) Limited
Gazipur
BDT
162.5
m
60%
Belgium
Novartis Pharma NV
Vilvoorde
EUR
72.1
m
100%
Sandoz NV
Vilvoorde
EUR
19.2
m
100%
Alcon - Couvreur NV
Puurs
EUR
110.6
m
100%
Bermuda
Novartis Investment Ltd.
Hamilton  2
USD
12 000
100%
Novartis Securities Investment Ltd.
Hamilton
CHF
30 000
100%
Novartis Finance Services Ltd.
Hamilton
CHF
20 000
100%
Triangle International Reinsurance Limited
Hamilton
CHF
1.0
m
100%
Trinity River Insurance Co Ltd.
Hamilton
USD
370 000
100%
Brazil
Novartis Biociências S.A.
São Paulo
BRL
507.1
m
100%
Sandoz do Brasil Indústria Farmacêutica Ltda.
Cambé, PR
BRL
190.0
m
100%
Canada
Novartis Pharmaceuticals Canada Inc.
Dorval, Quebec
CAD
1.2
m
100%
Sandoz Canada Inc.
Boucherville, Quebec
CAD
80.8
m
100%
Chile
Novartis Chile S.A.
Santiago de Chile
CLP
2.0
bn
100%
China
Beijing Novartis Pharma Co., Ltd.
Beijing
USD
30.0
m
100%
Novartis Pharmaceuticals (HK) Limited
Hong Kong
HKD
200
100%
China Novartis Institutes for BioMedical Research Co., Ltd.
Shanghai
USD
320.0
m
100%
Suzhou Novartis Technical Development Co., Ltd.
Changshu
USD
12.0
m
100%
Shanghai Novartis Trading Ltd.
Shanghai
USD
3.2
m
100%
Sandoz (China) Pharmaceutical Co., Ltd.
Zhongshan
USD
57.6
m
100%
Colombia
Novartis de Colombia S.A.
Santafé de Bogotá
COP
7.9
bn
100%
Croatia
Sandoz d.o.o. farmaceutska industrija
Zagreb
HRK
25.6
m
100%
Czech Republic
Novartis s.r.o.
Prague
CZK
51.5
m
100%
Sandoz s.r.o.
Prague
CZK
44.7
m
100%
Denmark
Novartis Healthcare A/S
Copenhagen
DKK
14.0
m
100%
Sandoz A/S
Copenhagen
DKK
12.0
m
100%
Ecuador
Novartis Ecuador S.A.
Quito
USD
4.0
m
100%
Egypt
Novartis Pharma S.A.E.
Cairo
EGP
1.3
bn
99.96%
Sandoz Egypt Pharma S.A.E.
New Cairo City
EGP
250 000
100%
Finland
Novartis Finland Oy
Espoo
EUR
459 000
100%

As at December 31, 2022
Share
capital1
Equity
interest
France
Novartis Groupe France S.A.
Rueil-Malmaison
EUR
903.0
m
100%
Novartis Pharma S.A.S.
Rueil-Malmaison
EUR
43.4
m
100%
Novartis Gene Therapies France SAS
Rueil-Malmaison
EUR
10 000
100%
Advanced Accelerator Applications S.A.
Rueil-Malmaison
EUR
9.6
m
99.23%
Advanced Accelerator Applications Molecular Imaging France
Saint-Genis-Pouilly
EUR
7.5
m
99.23%
CELLforCURE
Les Ulis
EUR
4.2
m
100%
Sandoz S.A.S.
Levallois-Perret
EUR
5.4
m
100%
Germany
Novartis Deutschland GmbH
Nuremberg
EUR
155.5
m
100%
Novartis Business Services GmbH
Wehr
EUR
25 000
100%
Novartis Pharma GmbH
Nuremberg
EUR
25.6
m
100%
Novartis Pharma Produktions GmbH
Wehr
EUR
2.0
m
100%
Sandoz International GmbH
Holzkirchen
EUR
100 000
100%
1 A Pharma GmbH
Holzkirchen
EUR
26 000
100%
HEXAL AG
Holzkirchen
EUR
93.7
m
100%
Salutas Pharma GmbH
Barleben
EUR
42.1
m
100%
Aeropharm GmbH
Rudolstadt
EUR
26 000
100%
Greece
Novartis (Hellas) S.A.C.I.
Metamorphosis / Athens
EUR
233.9
m
100%
Hungary
Novartis Hungary Healthcare Limited Liability Company
Budapest
HUF
545.6
m
100%
Sandoz Hungary Limited Liability Company
Budapest
HUF
883.0
m
100%
India
Novartis India Limited
Mumbai
INR
123.5
m
70.68%
Novartis Healthcare Private Limited
Mumbai
INR
60.0
m
100%
Sandoz Private Limited
Mumbai
INR
32.0
m
100%
Indonesia
PT. Novartis Indonesia
Jakarta
IDR
7.7
bn
100%
Ireland
Novartis Ireland Limited
Dublin
EUR
25 000
100%
Novartis Integrated Services Limited
Cork City
EUR
100
100%
Novartis Gene Therapies EU Limited
Dublin
EUR
100
100%
Israel
Novartis Israel Ltd.
Tel Aviv
ILS
1 000
100%
Italy
Novartis Farma S.p.A.
Milan
EUR
18.2
m
100%
Advanced Accelerator Applications (Italy) S.r.l.
Pozzilli
EUR
119 000
99.23%
Sandoz S.p.A.
Origgio
EUR
1.7
m
100%
Japan
Novartis Pharma K.K.
Tokyo
JPY
100.0
m
100%
Ciba-Geigy Japan Limited
Tokyo
JPY
100.0
m
100%
Sandoz K.K.
Tokyo
JPY
100.0
m
100%
Latvia
Novartis Baltics SIA
Riga
EUR
3.0
m
100%
Luxembourg
Novartis Investments S.à r.l.
Luxembourg City  2
USD
100.0
m
100%
Novartis Finance S.A.
Luxembourg City
USD
100 000
100%
Malaysia
Novartis Corporation (Malaysia) Sdn. Bhd.
Petaling Jaya
MYR
3.3
m
100%
Mexico
Novartis Farmacéutica, S.A. de C.V.
Mexico City
MXN
205.0
m
100%
Sandoz, S.A. de C.V.
Mexico City
MXN
468.2
m
100%
Morocco
Novartis Pharma Maroc SA
Casablanca
MAD
80.0
m
100%
Netherlands
Novartis Netherlands B.V.
Amsterdam
EUR
1.4
m
100%
Novartis Pharma B.V.
Amsterdam
EUR
4.5
m
100%
IDB Holland BV
Baarle-Nassau
EUR
18 000
99.23%
Sandoz B.V.
Almere
EUR
907 560
100%
New Zealand
Novartis New Zealand Ltd
Auckland
NZD
820 000
100%

As at December 31, 2022
Share
capital1
Equity
interest
Norway
Novartis Norge AS
Oslo
NOK
1.5
m
100%
Pakistan
Novartis Pharma (Pakistan) Limited
Karachi
PKR
6.7
bn
99.99%
Panama
Novartis Pharma (Logistics), Inc.
Panama City
USD
10 000
100%
Philippines
Novartis Healthcare Philippines, Inc.
Makati City
PHP
298.8
m
100%
Sandoz Philippines Corporation
Makati City
PHP
30.0
m
100%
Poland
Novartis Poland Sp. z o.o.
Warsaw
PLN
44.2
m
100%
Sandoz Polska Sp. z o.o.
Warsaw
PLN
25.6
m
100%
Lek S.A.
Strykow
PLN
11.4
m
100%
Portugal
Novartis Portugal, S.G.P.S., Lda.
Porto Salvo
EUR
500 000
100%
Novartis Farma - Produtos Farmacêuticos, S.A.
Porto Salvo
EUR
2.4
m
100%
Sandoz Farmacêutica, Lda.
Porto Salvo
EUR
499 900
100%
Romania
Novartis Pharma Services Romania S.R.L.
Bucharest
RON
3.0
m
100%
Sandoz S.R.L.
Targu-Mures
RON
119.5
m
100%
Russian Federation
Novartis Pharma LLC
Moscow
RUB
20.0
m
100%
Novartis Neva LLC
St. Petersburg
RUB
500.0
m
100%
JSC Sandoz
Moscow
RUB
57.4
m
100%
Saudi Arabia
Novartis Saudi Ltd.
Riyadh
SAR
30.0
m
100%
Singapore
Novartis (Singapore) Pte Ltd.
Singapore
SGD
100 000
100%
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd
Singapore
SGD
45.0
m
100%
Novartis Asia Pacific Pharmaceuticals Pte Ltd
Singapore
SGD
39.0
m
100%
Slovakia
Novartis Slovakia s.r.o.
Bratislava
EUR
2.0
m
100%
Slovenia
Lek Pharmaceuticals d.d.
Ljubljana
EUR
48.4
m
100%
Sandoz Pharmaceuticals d.d.
Ljubljana
EUR
1.5
m
100%
South Africa
Novartis South Africa (Pty) Ltd
Midrand
ZAR
86.3
m
100%
Sandoz South Africa (Pty) Ltd
Midrand
ZAR
3.0
m
100%
South Korea
Novartis Korea Ltd.
Seoul
KRW
24.5
bn
100%
Spain
Novartis Farmacéutica, S.A.
Barcelona
EUR
63.0
m
100%
Advanced Accelerator Applications Iberica, S.L.U.
Esplugues de Llobregat
EUR
22.6
m
99.23%
Sandoz Farmacéutica S.A.
Madrid
EUR
270 450
100%
Sandoz Industrial Products S.A.
Les Franqueses del Vallés / Barcelona
EUR
9.3
m
100%
Abadia Retuerta S.A.
Sardón de Duero / Valladolid
EUR
6.0
m
100%
Sweden
Novartis Sverige AB
Stockholm
SEK
5.0
m
100%
Switzerland
Novartis International AG
Basel
CHF
10.0
m
100%
Novartis Holding AG
Basel  2
CHF
100.2
m
100%
Novartis International Pharmaceutical Investment AG
Basel
CHF
100 000
100%
Novartis Bioventures AG
Basel
CHF
100 000
100%
Novartis Forschungsstiftung
Basel  3
--
--
--
Novartis Stiftung für Kaderausbildung
Basel  3
--
--
--
Novartis-Mitarbeiterbeteiligungsstiftung
Basel  3
--
--
--
Novartis Stiftung für Mensch und Umwelt
Basel  3
--
--
--
Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung
Basel  3
--
--
--
Novartis Overseas Investments AG
Basel
CHF
1.0
m
100%
Japat AG
Basel
CHF
50 000
100%
Novartis Pharma AG
Basel  2
CHF
350.0
m
100%
Novartis Pharma Services AG
Basel
CHF
20.0
m
100%
Novartis Pharma Schweizerhalle AG
Muttenz
CHF
18.9
m
100%
Novartis Pharma Stein AG
Stein
CHF
251 000
100%
Novartis Pharma Schweiz AG
Risch
CHF
5.0
m
100%
Cellerys AG
Schlieren
CHF
129 630
20%
Arctos Medical AG
Bern
CHF
360 020
100%
Novartis Innovative Therapies AG
Risch
CHF
100 000
100%
Advanced Accelerator Applications International SA
Geneva
CHF
9.3
m
99.23%
Sandoz AG
Basel  2
CHF
5.0
m
100%
Sandoz Pharmaceuticals AG
Risch
CHF
100 000
100%

As at December 31, 2022
Share
capital1
Equity
interest
Taiwan
Novartis (Taiwan) Co., Ltd.
Taipei
TWD
170.0
m
100%
Thailand
Novartis (Thailand) Limited
Bangkok
THB
302.0
m
100%
Turkey
Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S.
Istanbul
TRY
448.0
m
100%
Farmanova Saglik Hizmetleri Ltd. Sti.
Istanbul
TRY
6.7
m
100%
Sandoz Ilaç Sanayi ve Ticaret A.S.
Istanbul
TRY
880.0
m
99.99%
Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S.
Gebze - Kocaeli
TRY
96.0
m
100%
Ukraine
Sandoz Ukraine LLC
Kyiv
UAH
8.0
m
100%
United Arab Emirates
Novartis Middle East FZE
Dubai
AED
7.0
m
100%
United Kingdom
Novartis UK Limited
London
GBP
25.5
m
100%
Novartis Pharmaceuticals UK Limited
London
GBP
5.4
m
100%
Novartis Grimsby Limited
London
GBP
250.0
m
100%
Advanced Accelerator Applications (UK & Ireland)
London
GBP
100
99.23%
Neutec Pharma Limited
London
GBP
7.7
m
100%
Gyroscope Therapeutics Limited
London
GBP
1 492
100%
Sandoz Limited
Frimley / Camberley
GBP
2.0
m
100%
United States of America
Novartis Corporation
East Hanover, NJ
USD
72.2
m
100%
Novartis Finance Corporation
East Hanover, NJ  2
USD
1 000
100%
Novartis Capital Corporation
East Hanover, NJ
USD
1
100%
Novartis Services, Inc.
East Hanover, NJ
USD
1
100%
Novartis US Foundation
East Hanover, NJ  3
--
--
--
Novartis Pharmaceuticals Corporation
East Hanover, NJ  2
USD
650
100%
Advanced Accelerator Applications USA, Inc.
Millburn, NJ
USD
1
99.23%
Novartis Gene Therapies, Inc.
Bannockburn, IL
USD
1
100%
Novartis Technology LLC
East Hanover, NJ
--
--
--
Novartis Institutes for BioMedical Research, Inc.
Cambridge, MA
USD
1
100%
Cadent Therapeutics
Cambridge, MA
USD
0.1
100%
Endocyte, Inc.
East Hanover, NJ
USD
1
100%
Navigate BioPharma Services, Inc.
Carlsbad, CA
USD
1
100%
The Medicines Company
East Hanover, NJ
USD
1 000
100%
Sandoz Inc.
Princeton, NJ
USD
25 000
100%
Oriel Therapeutics, Inc.
Durham, NC
USD
50.0
m
100%
Fougera Pharmaceuticals Inc.
Melville, NY
USD
1
100%
Eon Labs, Inc.
Princeton, NJ
USD
1
100%
Venezuela
Novartis de Venezuela, S.A.
Caracas
VES
0
100%
Vietnam
Novartis Vietnam Company Limited
Ho Chi Minh City
VND
70
bn
100%
In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.
 1  Share capital may not reflect the taxable share capital and does not include any paid-in surplus.
 2  Significant subsidiary under SEC Regulation S-X Rule 1-02(w)
 3  Fully consolidated Foundation
m = million; bn = billion